EVNIN LUKE 4
4 · Werewolf Therapeutics, Inc. · Filed Dec 17, 2025
Insider Transaction Report
Form 4
EVNIN LUKE
Director
Transactions
- Sale
Common Stock
2025-12-15$1.07/sh−23,640$25,295→ 2,866,488 total(indirect: See Footnotes) - Sale
Common Stock
2025-12-16$1.05/sh−14,548$15,275→ 2,851,940 total(indirect: See Footnotes) - Sale
Common Stock
2025-12-17$1.14/sh−9,983$11,381→ 2,841,957 total(indirect: See Footnotes)
Footnotes (11)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.095 to $1.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares are held as follows: 304,378 by AM LLC, 1,922,046 by BV 2014, 128,196 by BV 2014(B), 66,156 by AM BV2014 and 421,181 by MPM OIF.
- [F2]The shares were sold as follows: 2,529 by MPM Asset Management LLC ("AM LLC"), 15,977 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,066 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 550 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,518 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F5]The shares are held as follows: 307,002 by AM LLC, 1,938,625 by BV 2014, 129,302 by BV 2014(B), 66,727 by AM BV2014 and 424,832 by MPM OIF.
- [F6]The shares were sold as follows: 1,556 by AM LLC, 9,832 by BV 2014, 656 by BV 2014(B), 339 by AM BV2014 and 2,165 by MPM OIF.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The shares are held as follows: 305,446 by AM LLC, 1,928,793 by BV 2014, 128,646 by BV 2014(B), 66,388 by AM BV2014 and 422,667 by MPM OIF.
- [F9]The shares were sold as follows: 1,068 by AM LLC, 6,747 by BV 2014, 450 by BV 2014(B), 232 by AM BV2014 and 1,486 by MPM OIF.